Gustavo Velasquez, MD, MPH

UCSF Center for Tuberculosis DEIAB Chair
UC TRAC CMC Member
Assistant Professor
Medicine

Dr. Velásquez is an Assistant Professor of Medicine in the Division of HIV, Infectious Diseases, and Global Medicine at the University of California, San Francisco. He is an infectious disease physician and clinical researcher focused on tuberculosis (TB) therapeutics. Based at the UCSF Center for Tuberculosis (tb.ucsf.edu), he works with the endTB consortium (endTB.org), the SMART4TB consortium (tbcenter.jhu.edu/smart4tb), and the AIDS Clinical Trials Group on Phase 2 and Phase 3 randomized controlled trials evaluating new shortened regimens for drug-susceptible and drug-resistant TB. He attends on the inpatient infectious diseases/HIV consult service and outpatient HIV and TB clinics at San Francisco General Hospital.

UCSF Center for Tuberculosis Leadership & Initiatives:
Chair/Lead, UCSF CTB Diversity, Equity, Inclusion, Accessibility Initiative 
UC TRAC Core Management Committee Member
SMART4TB UCSF Lead, Therapeutics 
BATS Rising Star 2023
BATS Planning Committee 2022
World TB Day Planning Committee 2022

Publications: 

Experience With Four-Month Rifapentine and Moxifloxacin-Based Tuberculosis Treatment in San Francisco.

Open forum infectious diseases

Louie JK, Agraz-Lara R, Velásquez GE, Phillips A, Szumowski JD

Pharmacokinetic-Pharmacodynamic Evidence from a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Ngo HX, Xu AY, Velásquez GE, Zhang N, Chang VK, Kurbatova EV, Whitworth WC, Sizemore E, Bryant K, Carr W, Weiner M, Dooley KE, Engle M, Dorman SE, Nahid P, Swindells S, Chaisson RE, Nsubuga P, Lourens M, Dawson R, Savic RM

Nine-month, all-oral regimens for rifampin-resistant tuberculosis

medRxiv

Guglielmetti L*, Khan U*, Velasquez GE*, Gouillou M, Abubakirov A, Baudin E, Berikova E, Berry C, Bonnet M, Cellamare M, Chavan V, Cox V, Dakenova Z, De Jong BC, Ferlazzo G, Karabayev A, Kirakosyan O, Kiria N, Kunda M, Lachenal N, Lecca L, McIlleron H, Motta I, Mucching-Toscano S, Mushtaque H, Nahid P, Oyewusi L, Panda S, Patil S, Phillips P, Ruiz J, Salahuddin N, Sanchez-Garavito E, Seung KJ, Ticona E, Trippa L, Vargas D, Wasserman S, Rich ML, Varaine F**, Mitnick CD**

Standards for clinical trials for treating TB.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease

du Cros P, Greig J, Alffenaar JC, Cross GB, Cousins C, Berry C, Khan U, Phillips PPJ, Velásquez GE, Furin J, Spigelman M, Denholm JT, Thi SS, Tiberi S, Huang GKL, Marks GB, Turkova A, Guglielmetti L, Chew KL, Nguyen HT, Ong CWM, Brigden G, Singh KP, Motta I, Lange C, Seddon JA, Nyang'wa BT, Maug AKJ, Gler MT, Dooley KE, Quelapio M, Tsogt B, Menzies D, Cox V, Upton CM, Skrahina A, McKenna L, Horsburgh CR, Dheda K, Marais BJ

Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial.

Trials

Patil SB, Tamirat M, Khazhidinov K, Ardizzoni E, Atger M, Austin A, Baudin E, Bekhit M, Bektasov S, Berikova E, Bonnet M, Caboclo R, Chaudhry M, Chavan V, Cloez S, Coit J, Coutisson S, Dakenova Z, De Jong BC, Delifer C, Demaisons S, Do JM, Dos Santos Tozzi D, Ducher V, Ferlazzo G, Gouillou M, Khan U, Kunda M, Lachenal N, LaHood AN, Lecca L, Mazmanian M, McIlleron H, Moreau M, Moschioni M, Nahid P, Osso E, Oyewusi L, Panda S, Pâquet A, Thuong Huu P, Pichon L, Rich ML, Rupasinghe P, Salahuddin N, Sanchez Garavito E, Seung KJ, Velásquez GE, Vallet M, Varaine F, Yuya-Septoh FJ, Mitnick CD, Guglielmetti L

An activist’s guide to shorter treatment for drug-resistant tuberculosis

McKenna L, Branigan D, Deborggraeve S, Frick M, Furin J, Galarza J, Gebhard A, Gupta S, Kaiser B, de Kruijf-Carter I, Kumar B, Mabote L, Mbenga M, Mirzayev F, Moses GK, Nguyen L, Nyang’wa BT, Pak S, Perrin C, Salazar-Austin N, Sari AH, Seidel S, Velasquez G, Waite R, Waning B, Wares F

Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis.

Lancet (London, England)

Reid M, Agbassi YJP, Arinaminpathy N, Bercasio A, Bhargava A, Bhargava M, Bloom A, Cattamanchi A, Chaisson R, Chin D, Churchyard G, Cox H, Denkinger CM, Ditiu L, Dowdy D, Dybul M, Fauci A, Fedaku E, Gidado M, Harrington M, Hauser J, Heitkamp P, Herbert N, Herna Sari A, Hopewell P, Kendall E, Khan A, Kim A, Koek I, Kondratyuk S, Krishnan N, Ku CC, Lessem E, McConnell EV, Nahid P, Oliver M, Pai M, Raviglione M, Ryckman T, Schäferhoff M, Silva S, Small P, Stallworthy G, Temesgen Z, van Weezenbeek K, Vassall A, Velásquez GE, Venkatesan N, Yamey G, Zimmerman A, Jamison D, Swaminathan S, Goosby E

Recent advances in the treatment of tuberculosis.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Motta I, Boeree M, Chesov D, Dheda K, Günther G, Horsburgh CR, Kherabi Y, Lange C, Lienhardt C, McIlleron HM, Paton NI, Stagg HR, Thwaites G, Udwadia Z, Van Crevel R, Velásquez GE, Wilkinson RJ, Guglielmetti L

Respiratory, Cardiac, and Neuropsychiatric Manifestations of Postacute Sequelae of Coronavirus Disease 2019 in Lima, Peru.

Open forum infectious diseases

Rahman RS, Tovar MA, Peinado J, Palomino JS, Ramirez C, Llanos-Zavalaga F, Peralta E, Valderrama G, Ramos Cordova LB, Sanchez Cortez LI, Rodriguez G, LaHood AN, Franke MF, Mitnick CD, Lecca L, Velásquez GE

Promise and Peril of Pretomanid-Rifamycin Regimens for Drug-Susceptible Tuberculosis.

American journal of respiratory and critical care medicine

Velásquez GE, Nahid P

Low detection rate of RT-PCR-confirmed COVID-19 using IgM/IgG rapid antibody tests in a large community sample in Lima, Peru.

BMC infectious diseases

Law S, Tovar MA, Franke MF, Calderon R, Palomino S, Valderrama G, Llanos F, Velásquez GE, Mitnick CD, Lecca L

Clinical Outcomes of Individuals with COVID-19 and Tuberculosis during the Pre-Vaccination Period of the Pandemic: A Systematic Review.

Journal of clinical medicine

Jhaveri TA, Fung C, LaHood AN, Lindeborg A, Zeng C, Rahman R, Bain PA, Velásquez GE, Mitnick CD

Diagnostic Performance Assessment of Saliva RT-PCR and Nasopharyngeal Antigen for the Detection of SARS-CoV-2 in Peru.

Microbiology spectrum

Calderón RI, Jhaveri TA, Tovar MA, Palomino JS, Barreda NN, Sanabria OM, Peinado J, Ramirez C, Llanos Zavalaga LF, Valderrama G, Franke MF, Mitnick CD, Lecca L, Velásquez GE

Prevalence of SARS-CoV-2 antibodies among market and city bus depot workers in Lima, Peru.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Tovar M, Peinado J, Palomino S, Llanos F, Ramírez C, Valderrama G, Calderón RI, Williams RB, Velásquez GE, Mitnick CD, Franke MF, Lecca L

Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial.

Trials

Guglielmetti L, Ardizzoni E, Atger M, Baudin E, Berikova E, Bonnet M, Chang E, Cloez S, Coit JM, Cox V, de Jong BC, Delifer C, Do JM, Tozzi DDS, Ducher V, Ferlazzo G, Gouillou M, Khan A, Khan U, Lachenal N, LaHood AN, Lecca L, Mazmanian M, McIlleron H, Moschioni M, O'Brien K, Okunbor O, Oyewusi L, Panda S, Patil SB, Phillips PPJ, Pichon L, Rupasinghe P, Rich ML, Saluhuddin N, Seung KJ, Tamirat M, Trippa L, Cellamare M, Velásquez GE, Wasserman S, Zimetbaum PJ, Varaine F, Mitnick CD

Disparities in SARS-CoV-2 Vaccination-to-Infection Risk During the COVID-19 Pandemic in Massachusetts.

JAMA Health Forum

Dryden-Peterson S, Velásquez GE, Stopka TJ, Davey S, Gandhi RT, Lockman S, Ojikutu BO

Disparities in SARS-CoV-2 Vaccination-to-Infection Risk, Massachusetts 2020-2021

medRxiv

Dryden-Peterson S, Velásquez GE, Stopka TJ, Davey S, Gandhi RT, Lockman S, Ojikutu BO

Disparities in SARS-CoV-2 Testing in Massachusetts During the COVID-19 Pandemic.

JAMA network open

Dryden-Peterson S, Velásquez GE, Stopka TJ, Davey S, Lockman S, Ojikutu BO

SARS-CoV-2 Testing Disparities in Massachusetts.

medRxiv : the preprint server for health sciences

Dryden-Peterson S, Velásquez GE, Stopka TJ, Davey S, Lockman S, Ojikutu B

Omadacycline for the Treatment of Mycobacterium abscessus Disease: A Case Series.

Open forum infectious diseases

Pearson JC, Dionne B, Richterman A, Vidal SJ, Weiss Z, Velásquez GE, Marty FM, Sax PE, Yawetz S

Delayed Relapse of Paracoccidioidomycosis in the Central Nervous System: A Case Report.

Open forum infectious diseases

Rahman R, Davies L, Mohareb AM, Peçanha-Pietrobom PM, Patel NJ, Solomon IH, Meredith DM, Tsai HK, Guenette JP, Bhattacharyya S, Urday S, Velásquez GE

The fourth national anti-tuberculosis drug resistance survey in Peru.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease

Quispe N, Asencios L, Obregon C, Velásquez GE, Mitnick CD, Lindeborg M, Jave H, Solari L

Quantitative assessment of the activity of antituberculosis drugs and regimens.

Expert review of anti-infective therapy

Chirehwa MT, Velásquez GE, Gumbo T, McIlleron H

Reply to te Brake et al.: Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis.

American journal of respiratory and critical care medicine

Velásquez GE, Brooks MB, Coit JM, Sánchez Garavito E, Calderón RI, Jiménez J, Tintaya K, Peloquin CA, Osso E, Lecca L, Davies GR, Mitnick CD

Outcomes of a Career Development Program for Underrepresented Minority Investigators in the AIDS Clinical Trials Group.

Open forum infectious diseases

Velásquez GE, Huaman MA, Powell KR, Cohn SE, Swaminathan S, Outlaw M, Schulte G, McNeil Q, Currier JS, Del Rio C, Castillo-Mancilla J

Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial.

American journal of respiratory and critical care medicine

Velásquez GE, Brooks MB, Coit JM, Pertinez H, Vargas Vásquez D, Sánchez Garavito E, Calderón RI, Jiménez J, Tintaya K, Peloquin CA, Osso E, Tierney DB, Seung KJ, Lecca L, Davies GR, Mitnick CD

Making up the difference: ensuring the bioequivalence of fixed-dose combinations for tuberculosis.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease

Velásquez GE, Davies GR, Mitnick CD

A Case of Disseminated Histoplasmosis in a Patient with Rheumatoid Arthritis on Abatacept.

Journal of general internal medicine

Jain N, Doyon JB, Lazarus JE, Schaefer IM, Johncilla ME, Agoston AT, Dalal AK, Velásquez GE

Prevalence of pyrazinamide resistance and Wayne assay performance analysis in a tuberculosis cohort in Lima, Peru.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease

Calderón RI, Velásquez GE, Becerra MC, Zhang Z, Contreras CC, Yataco RM, Galea JT, Lecca LW, Kritski AL, Murray MB, Mitnick CD

Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis.

Antimicrobial agents and chemotherapy

Peloquin CA, Velásquez GE, Lecca L, Calderón RI, Coit J, Milstein M, Osso E, Jimenez J, Tintaya K, Sanchez Garavito E, Vargas Vasquez D, Mitnick CD, Davies G

Nutritional Status and Tuberculosis Risk in Adult and Pediatric Household Contacts.

PloS one

Aibana O, Acharya X, Huang CC, Becerra MC, Galea JT, Chiang SS, Contreras C, Calderon R, Yataco R, Velásquez GE, Tintaya K, Jimenez J, Lecca L, Murray MB

Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis.

Antimicrobial agents and chemotherapy

Velásquez GE, Calderon RI, Mitnick CD, Becerra MC, Huang CC, Zhang Z, Contreras CC, Yataco RM, Galea JT, Lecca LW, Murray MB

Impact of HIV on mortality among patients treated for tuberculosis in Lima, Peru: a prospective cohort study.

BMC infectious diseases

Velásquez GE, Cegielski JP, Murray MB, Yagui MJ, Asencios LL, Bayona JN, Bonilla CA, Jave HO, Yale G, Suárez CZ, Sanchez E, Rojas C, Atwood SS, Contreras CC, Santa Cruz J, Shin SS

Time From Infection to Disease and Infectiousness for Ebola Virus Disease, a Systematic Review.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Velásquez GE, Aibana O, Ling EJ, Diakite I, Mooring EQ, Murray MB

Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Velásquez GE, Becerra MC, Gelmanova IY, Pasechnikov AD, Yedilbayev A, Shin SS, Andreev YG, Yanova G, Atwood SS, Mitnick CD, Franke MF, Rich ML, Keshavjee S

Targeted drug-resistance testing strategy for multidrug-resistant tuberculosis detection, Lima, Peru, 2005-2008.

Emerging infectious diseases

Velásquez GE, Yagui M, Cegielski JP, Asencios L, Bayona J, Bonilla C, Jave HO, Yale G, Suárez C, Atwood S, Contreras CC, Shin SS